Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?

Affiliations

¹ School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: s.bellary@aston.ac.uk.
² University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; Centre for Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Comment

Srikanth Bellary et al. Lancet Diabetes Endocrinol. 2020 Nov.

. 2020 Nov;8(11):870-871.

doi: 10.1016/S2213-8587(20)30301-6. Epub 2020 Sep 21.

¹ School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: s.bellary@aston.ac.uk.
² University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; Centre for Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

No abstract available

Comment on

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
Mann JFE, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, Seufert J, Tadayon S, Vilsbøll T. Mann JFE, et al. Lancet Diabetes Endocrinol. 2020 Nov;8(11):880-893. doi: 10.1016/S2213-8587(20)30313-2. Epub 2020 Sep 21. Lancet Diabetes Endocrinol. 2020. PMID: 32971040 Clinical Trial.